Humacyte (HUMA) Non-cash Items (2020 - 2026)

Humacyte (HUMA) reported Non-cash Items of $8.5 million for Q1 2026, down 47.59% quarter-over-quarter from $16.2 million in Q4 2024.

Humacyte (HUMA) Non-cash Items (2020 - 2026) Analysis & Trends

Humacyte (HUMA) has 4 years of Non-cash Items data on file, last reported at $8.5 million in Q1 2026.

Non-cash Items for Q1 2026 came in at $8.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $8.5 million (changed N/A YoY), and the FY2025 annual result was $7.7 million, down 52.77% from the prior year.
Non-cash Items retreated to $8.5 million in Q1 2026 per HUMA's latest filing, from $16.2 million in the prior quarter.
Over five years, Non-cash Items peaked at $16.2 million in Q4 2024 and troughed at $8.5 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Humacyte	183.21 Mn	134.67 Mn	-1.54 Mn

Download Data